Williams Jones Wealth Management LLC. boosted its holdings in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 765.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 134,072 shares of the company's stock after purchasing an additional 118,572 shares during the quarter. Williams Jones Wealth Management LLC. owned about 0.19% of Personalis worth $775,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the company. abrdn plc bought a new stake in shares of Personalis during the 4th quarter valued at $1,722,000. Dimensional Fund Advisors LP lifted its stake in shares of Personalis by 144.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock valued at $2,372,000 after purchasing an additional 242,141 shares during the period. Barclays PLC raised its stake in Personalis by 67.1% during the fourth quarter. Barclays PLC now owns 109,368 shares of the company's stock valued at $632,000 after buying an additional 43,900 shares during the last quarter. Jane Street Group LLC raised its stake in Personalis by 144.3% during the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company's stock valued at $2,320,000 after buying an additional 237,033 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Personalis in the fourth quarter worth $64,000. Institutional investors and hedge funds own 61.91% of the company's stock.
Wall Street Analyst Weigh In
PSNL has been the topic of several research analyst reports. Guggenheim assumed coverage on Personalis in a research report on Thursday, May 15th. They issued a "buy" rating and a $6.00 price objective on the stock. Craig Hallum assumed coverage on Personalis in a research note on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective on the stock. HC Wainwright increased their target price on Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $7.67.
Get Our Latest Stock Report on PSNL
Personalis Price Performance
Shares of NASDAQ:PSNL traded up $0.16 during trading on Friday, reaching $4.78. The company had a trading volume of 484,344 shares, compared to its average volume of 1,012,498. The firm has a market capitalization of $422.19 million, a price-to-earnings ratio of -2.85 and a beta of 1.83. The stock's fifty day moving average price is $3.88 and its 200 day moving average price is $4.45. Personalis, Inc. has a fifty-two week low of $1.14 and a fifty-two week high of $7.20.
Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The business had revenue of $20.61 million for the quarter, compared to the consensus estimate of $17.41 million. On average, equities analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.
About Personalis
(
Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
See Also
Before you consider Personalis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.
While Personalis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
